Update in treatment of Chagas disease

Current Opinion in Infectious Diseases

Volumn 24, Issue 5, 2011, Pages 428-434

  Le Loup, Guillaume ^a,b,c   Pialoux, Gilles ^a   Lescure, François Xavier ^a  

^a UNIVERSITÉ PARIS EST   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

chronic Chagas disease; drugs; follow up; treatment

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX; NITROIMIDAZOLE; POSACONAZOLE;

ANOREXIA; CARDIOMYOPATHY; CHAGAS DISEASE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FOLLOW UP; HEADACHE; HEART FUNCTION; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL PROCEDURES; IRRITABILITY; MOOD DISORDER; NAUSEA; ORGAN INJURY; PARESTHESIA; PERIPHERAL NEUROPATHY; PETECHIA; POLYMERASE CHAIN REACTION; PRURITUS; REVIEW; SIDE EFFECT; SLEEP DISORDER; URTICARIA; VOMITING; WEIGHT REDUCTION;

CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPROMISED HOST; NITROIMIDAZOLES; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 80052453698     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834a667f     Document Type: Review

References (54)

1. Lescure FX, Le LoupG, Freilij H, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010; 10:556-570.
2. Aufderheide AC, Salo W, Madden M, et al. A 9000-year record of Chagas' disease. Proc Natl Acad Sci USA 2004; 101:2034-2039.
3. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010; 115:14-21.
4. Bastos CJ, Aras R, Mota G, et al. Clinical outcomes of thirteen patients with acute Chagas disease acquired through oral transmission from two urban outbreaks in northeastern Brazil. PLoS Negl Trop Dis 2010; 4:e711.
5. Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010; 201:1308-1315.
6. Bacal F, Silva CP, Pires PV, et al. Transplantation for Chagas' disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transplant 2010; 24:E29-E34.
7. Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156:37-43. (Pubitemid 351862295)
8. Higuchi MD, Ries MM, Aiello VD, et al. Association of an increase in CD8 T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997; 56:485-490.
9. Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart desease. Am J Trop Med Hyg 2004; 70:210-220. (Pubitemid 38200528)
10. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 1999; 180:480-486. (Pubitemid 30256331)
11. Del Puerto R, Nishizawa JE, Kikuchi M, et al. Lineage analysis of circulating Trypanosoma cruzi parasites and their association with clinical forms of Chagas disease in Bolivia. PLoS Negl Trop Dis 2010; 4:e687.
12. Virreira M, Truyens C, Alonso-Vega C, et al. Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns. Am J Trop Med Hyg 2007; 77:102-106. (Pubitemid 351844359)
13. Coura JR, Junqueira AC, Fernandes O, et al. Emerging Chagas disease in Amazonian Brazil. Trends Parasitol 2002; 18:171-176. (Pubitemid 34606845)
14. Borges M, Da Silva AC, Sereno D, Ouaissi A. Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor. Immunology 2003; 109:147-155. (Pubitemid 36577985)
15. Reis DD, Jones EM, Tostes S Jr, et al. Characterization of inflammatory infiltrates in chronic Chagasic myocardial lesions: presence of tumor necrosis factor-alpha cells and dominance of granzyme A , CD8 lymphocytes. Am J Trop Med Hyg 1993; 48:637-644. (Pubitemid 23187192)
16. Ribeiro BM, Crema E, Rodrigues V Jr. Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease. Hum Immunol 2008; 69:484-489.
17. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 2008; 8:510-518.
18. Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Dev Ther 2010; 4:243-253.
19. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388-1402.
20. Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011; 127:e212-e218.
21. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7:157-163.
22. Pinazo MJ, Muñ oz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010; 54:4896-4899.
23. Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 2010; 51:e69-e75.
24. Guedes PM, Silva GK, Gutierrez FR, Silva JS. Current status of Chagas disease chemotherapy. Expert Rev Anti Infect Ther 2011; 9:609-620.
25. Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000; 44:150-155. (Pubitemid 30010686)
26. Pinazo MJ, Espinosa G, Gá llego M, et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010; 82:583-587.
27. Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21:27-38. (Pubitemid 36043972)
28. Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979-2986.
29. Cencig S, Coltel N, Truyens C, Carlier Y. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with ambisome. Plos Negl Trop Dis 2011; 5:e1216.
30. Adesse D, Azzam EM, Meirelles M N, et al. Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob Agents Chemother 2011; 55:203-210.
31. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55-68.
32. Garzoni LR, Waghabi MC, Baptista MM, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004; 23:286-290. (Pubitemid 38283598)
33. Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagas encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9:324-330.
34. Duffy T, Bisio M, Altcheh J, Burgos JM, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in Chagas disease patients. PLoS Negl Trop Dis 2009; 3:e419.
35. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzispecific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49:1675-1684.
36. Araú jo-Jorge TC, Waghabi MC, Soeiro Mde N, et al. Pivotal role for TGF-beta in infectious heart disease: the case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev 2008; 19:405-413.
37. Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8 T central memory response in chronic Chagas disease. Nat Med 2008; 14:542-550. (Pubitemid 351655210)
38. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724-734. (Pubitemid 46780632)
39. Pérez-Molina JA, Pérez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139-1147.
40. Veiga MF, Rodrigues IF, Cardinalli-Neto A, et al. Clinical course of patients with chronic systolic heart failure due to the association of Chagas disease and systemic arterial hypertension. Int J Cardiol 2011; 149:122-124.
41. Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005; 36:123-129. (Pubitemid 41030627)
42. Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007; 45:1435-1442. (Pubitemid 351411872)
43. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of secondstage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007; 195:322-329. (Pubitemid 46146108)
44. Van Griensven J, Balasegaram M, Meheus F, et al. Combination therapy for visceral leishmaniasis [review]. Lancet Infect Dis 2010; 10:184-194.
45. Ferraz ML, Gazzinelli RT, Alves RO, et al. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007; 51:1359-1364. (Pubitemid 46586817)
46. WHO consultation on international biological reference preparations for Chagas disease test. 2007. http://www.who.int/bloodproducts/ref-materials/WHO- Report-1st-Chagas-BRP-consultation-7-2007-final.pdf [accessed July 2011].
47. Brasil PE, De Castro L, Hasslocher-Moreno AM, et al. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis 2010; 10:337.
48. Frade AF, Luquetti AO, Prata A, Ferreira AW. Western blotting method (TESAcruzi) as a supplemental test for confirming the presence of anti-Trypanosoma cruzi antibodies in finger prick blood samples from children aged 0-5 years in Brazil. Acta Trop 2011; 117:10-13.
49. Matos CS, Coelho-Dos-Reis JG, Rassi A, et al. Applicability of an optimized nonconventional flow cytometry method to detect anti-Trypanosoma cruzi immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease. J Immunol Methods 2011; 369:22-32.
50. Wendling AP, Vitelli-Avelar DM, Sathler-Avelar R, et al. The use of IgG antibodies in conventional and nonconventional immunodiagnostic tests for early prognosis after treatment of Chagas disease. J Immunol Methods 2011; 370:24-34.
51. Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011; 5:e931.
52. Murcia L, Carrilero B, Muñ oz MJ, et al. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a nondisease-endemic country. J Antimicrob Chemother 2010; 65:1759-1764.
53. Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9:324-330.
54. Pinazo MJ, Miranda B, Rodríguez-Villar C, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev 2011; 25:91-101.